Click, Otsuka partner on digital therapy for depression

Click Therapeutics Inc. (San Francisco, Calif.) partnered with Otsuka America Inc. to develop and commercialize CT-152, a digital therapy to treat major depressive disorder (MDD).

Otsuka said it will pay Click up to $10 million in upfront and regulatory milestone payments and an estimated $20 million in development funding; Click is eligible for up to $272 million in commercial milestones, plus double-digit tiered royalties. Otsuka America will be responsible for global commercialization of the software app, for which the companies intend to file regulatory applications under FDA's new software as a medical device (SaMD) framework (see "FDA Launching New Digital Health Regulatory Framework")...